Bionano Genomics, Inc. (BNGO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bionano Genomics, Inc. on January 24, 2025, with the earliest event reported on the same date. The filing details a material corporate action approved by stockholders at a Special Meeting held on January 15, 2025.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a capital structure adjustment.
Material Changes
- Reverse Stock Split: The Company effected a 1:60 reverse stock split effective at 5:00 p.m. Eastern Time on January 24, 2025.
- Share Conversion: Every 60 shares of issued and outstanding common stock were automatically converted into one share.
- Equity Adjustments: Proportionate adjustments were made to the exercise prices and share counts for all outstanding stock options, restricted stock units (RSUs), and warrants. The number of shares reserved under equity compensation plans was also reduced proportionately.
- Fractional Shares: No fractional shares were issued; stockholders entitled to fractional shares received cash payments in lieu thereof.
- Trading Status: Common stock began trading on The Nasdaq Capital Market on a split-adjusted basis on January 27, 2025.
- Identification: The new CUSIP number for the common stock is 09075F404.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard implications of a reverse stock split. The primary purpose of the split is to adjust the share price and count, which does not alter any stockholder's percentage ownership (except where fractional shares are cashed out).
Investor Verification Checklist
- Verify the new CUSIP number (09075F404) for trading and record-keeping purposes.
- Confirm the adjusted number of shares held and any cash received for fractional shares.
- Review the adjusted exercise prices and share quantities for any outstanding stock options, RSUs, or warrants.
- Monitor the stock's trading volume and price on The Nasdaq Capital Market starting January 27, 2025.